Belumosudil 200 mg QD
Sponsors
Kadmon, a Sanofi Company, The Methodist Hospital Research Institute
Conditions
Chronic Graft-versus-host-diseaseRejection Chronic Renal
Phase 2
Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213
CompletedNCT05305989
Start: 2022-02-23End: 2024-06-06Updated: 2025-05-02
Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
Enrolling by invitationNCT06751602
Start: 2025-09-11End: 2028-03-30Target: 40Updated: 2025-11-12